ATH 0.00% 0.3¢ alterity therapeutics limited

Later this month, page-4

  1. 1,560 Posts.
    lightbulb Created with Sketch. 2
    LOL Yes, kad's many claims including the FDA's approval of Reach2HD Phase III trial design have been debunked.

    Tenet #1 of successful investing: If doing your own due diligence isn't working, find an experienced unbiased source for information. Avoid the married-to-a-failing-stock-for years type. It will do well for your health- physical and financial.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.